After Friday comments by Trump that the US would be back in business with or without  a vaccine, a number of other world leaders were su...

Whereas my last blog  considered lung-targeted RNAi for addressing COVID19, this entry will look at what a liver-directed RNAi approach c...

This is a time where the biotech industry has to mobilize resources to mitigate the impact of pandemic SARS-CoV-2.   Nucleic acid-bas...

RNAi Therapeutics have turned the corner to being a generally accepted drug modality.   Following years of ridicule and benign neglect, t...

HBV RNAi or Nothing It is now 4 years that Wunderkind Vivek Ramaswamy handed you a bag of worthless small molecules for half of what...

At least, this is what Big Pharma and Biotech is saying right now following deals between pure-play RNAi companies Arrowhead Pharmaceutic...

Yesterday, Arrowhead revealed the abstract for data on its new HBV RNAi drug candidate to be presented at the big annual Liver Meeting i...